According to the latest research, low SMARCA4 expression and SMARCA2 overexpression are associated with platinum resistance in high-grade serous ovarian cancer (HGSC) cells, possibly related to substantial changes in chromatin accessibility, the activation of fibroblast growth factor (FGF) signaling, the activation of the MAPK pathway, and reduced apoptosis [247]. Here, SMARCA2 is linked to ovarian serous adenocarcinoma.